A Review of the Neuropharmacology of Bupropion, a Dual Norepinephrine and Dopamine Reuptake Inhibitor
Open accessThe DOI matches its Crossref record; 95 of the 95 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The neurochemical and biological effects of antidepressant medications have become better defined over the last decade. When the anti-depressant bupropion was introduced in the United States in 1989, the specific pharmacologic basis of its clinical effects was uncertain. Research conducted over the past decade has significantly advanced the understanding of the neuropharmacology of bupropion and has demonstrated a novel mechanism of antidepressant activity. This article discusses the mechanism of action of bupropion and relates the drug's neuropharmacologic effects to its clinical efficacy and tolerability profiles. DATA SOURCES: Data were obtained via the MEDLINE database in an English-language search spanning the period 1965 to May 2002 and using the search terms bupropion, bupropion SR, and antidepressants, as well as from the manufacturer's bupropion databases. CONCLUSIONS: The preclinical and clinical data show that bupropion acts via dual inhibition of norepinephrine and dopamine reuptake and is devoid of clinically significant serotonergic effects or direct effects on postsynaptic receptors. Dual norepinephrine and dopamine reuptake inhibition is associated with a unique clinical profile. Bupropion has demonstrated efficacy comparable to that of other antidepressants. However, because bupropion is a selective norepinephrine and dopamine reuptake inhibitor with no serotonergic activity, common antidepressant-associated side effects, such as sexual dysfunction, weight gain, and sedation, are not associated with bupropion therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Bupropion is a second-generation AD that acts as a selective inhibitor of catecholamines' (noradrenaline and dopamine) reuptake, devoid of any serotonergic; antihistamine; or anticholinergic properties (Stahl et al., 2004).”
From Is There a Potential of Misuse for Venlafaxine and Bupropion? (2018) · cites this paper as Stahl et al., 2004
In the citing paper
“Inhibition of catecholamine reuptake is one of bupropion’s mechanisms of action [215].”
From Mechanistic insights into nicotine withdrawal (2011) · cites this paper as [215]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Selective serotonin reuptake inhibitors (SSRIs) versus other antidepressants for depression
Geddes, J. R., Freemantle, N., Mason, J. M., Eccles, M., & Boynton, J. R. (1999) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001851 · Cited by 125
RetractedGoodman & Gilman's The Pharmacological Basis of Therapeutics
Brunton, L. L. (1985) · Cited by 7,321
Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants
Santarelli, L., Saxe, M., Gross, C., Surget, A., Battaglia, F., Dulawa, S., Weisstaub, N., Lee, J., Duman, R., Arancio, O., et al. (2003) · Science · doi:10.1126/science.1083328 · Cited by 4,321
The cellular neurobiology of depression
Manji, H. K., Drevets, W. C., & Charney, D. S. (2001) · Nature Medicine · doi:10.1038/87865 · Cited by 1,182 · cited 1×
“cause depression and modulate responses to antidepressants.(14,16,19) Several observations support an “upstream””
BackgroundUntreated Depression and Hippocampal Volume Loss
Sheline, Y. I., Gado, M. H., & Kraemer, H. C. (2003) · American Journal of Psychiatry · doi:10.1176/appi.ajp.160.8.1516 · Cited by 1,180 · cited 1×
“Antidepressants may thus play a neuroprotective role, a possibility supported by observations that hippocampal neurogenesis may be required for the behavior effects of antidepressants in mice(23) and that progressive loss of hippocampal volume occurs during chronically untreated depression in humans.(24,25)”
BackgroundPharmacological profile of antidepressants and related compounds at human monoamine transporters
Tatsumi, M., Groshan, K., Blakely, R. D., & Richelson, E. (1997) · European Journal of Pharmacology · doi:10.1016/s0014-2999(97)01393-9 · Cited by 939 · cited 1×
“For example, antidepressants differ by more than 1000fold in potency at inhibiting monoamine reuptake, yet their efficacies are comparable and seemingly unrelated to potency.(21) Third, although all antidepressants enhance monoaminergic neurotransmission, they do so via disparate mechanisms, consistent with the possib…”
Background(2000) · PubMed · Cited by 685
Bupropion: a review of its mechanism of antidepressant activity.
Ascher, J. A., Cole, J. O., Colin, J. N., Feighner, J. P., Ferris, R. M., Fibiger, H. C., Golden, R. N., Martin, P., Potter, W. Z., & Richelson, E. (1995) · PubMed · Cited by 680
Prevalence of Sexual Dysfunction Among Newer Antidepressants
Clayton, A. H., Pradko, J. F., Croft, H. A., Montano, C. B., Leadbetter, R. A., Bolden-Watson, C., Bass, K. I., Donahue, R. M. J., Jamerson, B. D., & Metz, A. (2002) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v63n0414 · Cited by 542
Self-citation
Research works printed but not linked: 27
- Ferris RM, Cooper BR. Mechanism of antidepressant activity of bupropion. J Clin Psychiatry Monograph. 1993;11(1):2–14. [PubMed] [Google Scholar]
- GlaxoSmithKline. data on file, Research Triangle Park, NC. 2002. [Google Scholar]
- Stahl SM. Essential Psychopharmacology. 2nd ed. New York, NY: Cambridge University Press. 2000 [Google Scholar]
- Remeron [package, insert]. West Orange, NJ: Organon. 2002. [Google Scholar]
- Serzone [package, insert]. Princeton, NJ: Bristol-Myers Squibb Company. 2002. [Google Scholar]
- Holden C. ed. Random samples: don't go off the Prozac. Science. 2003 301:760–761. [Google Scholar]
- Szabó Z, Àrgyelán M, and Kanyó B. et al. The effect of bupropion on the activity of dopamine transporter in depression: preliminary results [abstract]. Eur Neuropsychopharmacol. 2003 13(suppl 4):S210. [Google Scholar]
- American Psychiatric Association. Major Depressive Disorder: A Patient and Family Guide, 2001. Available at: www.psych.org. Accessed June 7, 2001. [Google Scholar]
- Geddes JR, Freemantle N, and Mason J. et al. SSRIs versus other anti-depressants for depressive disorder. Cochrane Database Syst Rev 2000(2):CD001851. [DOI] [PubMed] [Google Scholar]
- Thase ME, Haight BR, and Richard NE. et al. Remission rates following therapy with bupropion or SSRIs. Presented at the 156th annual meeting of the American Psychiatric Association. 17–22May2003 San Francisco, Calif. [Google Scholar]
- Boyer WF, Feighner JP. The combined use of fluoxetine and bupropion [poster]. Presented at the 146th annual meeting of the American Psychiatric Association. 22–27May1993 San Francisco, Calif. [Google Scholar]
- Ramasubbu R. Treatment of resistant depression by adding noradrenergic agents to lithium augmentation of SSRIs. Ann Pharmacother. 2002;36:634–640. doi: 10.1345/aph.10408. [DOI] [PubMed] [Google Scholar] · doi:10.1345/aph.10408 · Paper page
- Spier SA. Use of bupropion with SRIs and venlafaxine. Depress Anxiety. 1998;7:73–75. [PubMed] [Google Scholar]
- Yeghiya M, Danielyan A, and Khachatur G. et al. Augmentation of SSRIs with bupropion in treatment resistant depression in adolescents [abstract]. Presented at the 156th annual meeting of the American Psychiatric Association. 17–22May2003 San Francisco, Calif. [Google Scholar]
- DeBattista C, Solvason HB, and Fleming S. et al. A placebo-controlled, double-blind study of bupropion SR in the treatment of SSRI-induced sexual dysfunction [poster]. Presented at the 154th annual meeting of the American Psychiatric Association. 5–10May2001 New Orleans, La. [DOI] [PubMed] [Google Scholar]
- Solvason HB, DeBattista C, and Kendrick E. et al. Bupropion SR in the treatment of SSRI-induced sexual dysfunction [poster]. Presented at the 40th annual meeting of the New Clinical Drug Evaluation Unit Program (NCDEU). May 30–June 2, 2000 Boca Raton, Fla. [Google Scholar]
- Johnston JA, Schmidt G, and Ascher J. et al. Pharmacokinetic optimization of bupropion SR for smoking cessation. Drugs. 2002 62(suppl 2):11–24. [DOI] [PubMed] [Google Scholar]
- Hudziak JJ, Wilens TE, and Rosenthal NE. et al. The efficacy of extended-release bupropion in adult ADHD [poster]. Presented at the 42nd annual meeting of the American College of Neuropsychopharmacology. 7–11December2003 San Juan, Puerto Rico. [Google Scholar]
- Rosenthal NE, Modell JG, and Harriett A. et al. Wellbutrin XL for the prevention of seasonal depressive episodes [poster]. Presented at the 42nd annual meeting of the American College of Neuropsychopharmacology. 7–11December2003 San Juan, Puerto Rico. [Google Scholar]
- Clayton AH, West SG. The effects of antidepressants on human sexuality. Primary Psychiatry. 2003;10:62–70. [Google Scholar]
- Westlund R, Haight BR, and Harriett A. et al. Effect on body weight of bupropion in patients with major depression [poster]. Presented at the 16th Annual US Psychiatric & Mental Health Congress. 6–9November2003 Orlando, Fla. [Google Scholar]
- Celexa [package, insert]. St Louis, Mo: Forest Laboratories. 2002. [Google Scholar]
- Prozac [package, insert]. Indianapolis, Ind: Eli Lilly and Company. 2002. [Google Scholar]
- Paxil [package, insert]. Research Triangle Park, NC: GlaxoSmithKline. 2002. [Google Scholar]
- Zoloft [package, insert]. New York, NY: Pfizer Inc. 2002. [Google Scholar]
- Effexor [package, insert]. Philadelphia, Pa: Wyeth. 2002. [Google Scholar]
- Wellbutrin [package, insert]. Research Triangle Park, NC: GlaxoSmithKline. 2002. [Google Scholar]
Cited by
Items 301–400 of 510
Sluggish retrieval of positive memories in depressed adults
Maksimovskiy, A. L., Okine, C., Cataldo, A. M., & Dillon, D. G. (2022) · Cognitive Affective & Behavioral Neuroscience · doi:10.3758/s13415-022-01010-2 · Cited by 8
Childress, A. C. (2024) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2024.2358987 · Cited by 8
“Bupropion, a DA and NE reuptake inhibitor, had a SMD for adults of −0.46 (95% CI −0.85 to −0.07) [18,20].”
BackgroundInfluentialAltered local intrinsic neural activity and molecular architecture in internet use disorders
Ma, L., Tao, Q., Dang, J., Sun, J., Niu, X., Zhang, M., Kang, Y., Wang, W., Cheng, J., Han, S., et al. (2024) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2024.111052 · Cited by 8
“Moreover, in clinical pharmacology, bupropion can regulate dopamine release and inhibit dopamine reuptake, suggesting the neural mechanism of treating IGD (Stahl et al., 2004).”
BackgroundWittenkeller, L. M., Gudelsky, G. A., Winhusen, T. M., & Amato, D. (2025) · British Journal of Pharmacology · doi:10.1111/bph.70181 · Cited by 10
“…treatment for nicotine use disorder using nicotine replacement therapy, bupropion, or other antidepressants (NIDA, 2020), work as surro-gates of dopamine to stimulate the reward system and reduce the need for nicotine consumption (Di Ciano et al., 2016; Stahl et al., 2004; Zakiniaeiz et al., 2022).”
Cui, Y., Engelmann, J. M., Xian, J. Z., Minnix, J. A., Lam, C. Y., Karam‐Hage, M., Cinciripini, P. M., & Robinson, J. D. (2017) · International Journal of Psychophysiology · doi:10.1016/j.ijpsycho.2017.12.001 · Cited by 7
“It is also a dopaminergic and noradrenergic reuptake inhibitor (Stahl et al., 2004).”
BackgroundDoes Bupropion Increase Anxiety? A Naturalistic Study Over 12 Weeks
Poliacoff, Z., Belanger, H. G., & Winsberg, M. E. (2023) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000001658 · Cited by 7
Dołoto, A., Bąk, E., Batóg, G., Piątkowska‐Chmiel, I., & Herbet, M. (2024) · Pharmacological Reports · doi:10.1007/s43440-024-00611-7 · Cited by 8
“Bupropion belongs to the group of selective norepinephrine and dopamine reuptake inhibitors [77].”
BackgroundBehavioral Interventions in Tobacco Dependence
Leone, F. T., & Evers‐Casey, S. (2009) · Primary Care Clinics in Office Practice · doi:10.1016/j.pop.2009.04.002 · Cited by 8
Dennison, J., Puri, A., Warrington, S., Endo, T., Adeloye, T., & Johnston, A. E. (2018) · Clinical Pharmacology in Drug Development · doi:10.1002/cpdd.578 · Cited by 7
Parris, M. S., Marver, J. E., Chaudhury, S. R., Ellis, S. P., Metts, A. V., Keilp, J. G., Burke, A. K., Oquendo, M. A., Mann, J. J., & Grunebaum, M. F. (2018) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000225 · Cited by 9
Dextromethorphan and bupropion reduces high level remifentanil self-administration in rats
Blair, G., Wells, C., Ko, A., Modarres, J., Pace, C., Davis, J. M., Rezvani, A. H., Rose, J. E., & Levin, E. D. (2020) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2020.172919 · Cited by 7
Deang, K. T., Sidi, H., ZAKARIA, R. H., Adam, R. L., Das, S., Hatta, N. H., Hatta, M. H., & Wee, K. W. (2017) · Current Drug Targets · doi:10.2174/1389450118666170511145628 · Cited by 10
Nukitram, J., Kumarnsit, E., & Cheaha, D. (2022) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2022.11.003 · Cited by 6
“Aside from being a DA reuptake inhibitor of BP that can increase DA neurotransmission in the NAc (Stahl et al., 2004), it is also found to suppress the activity of VTA GABAergic interneurons dramatically (Amirabadi et al.”
Fan, P., Zeng, L., Ding, Y., Kofler, J., Silverstein, J. C., Krivinko, J. M., Sweet, R. A., & Wang, L. (2023) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12979 · Cited by 8
Ecstasy, legal highs and designer drug use: A Canadian perspective
Hudson, A. L., Lalies, M. D., Baker, G. B., Wells, K., & Aitchison, K. J. (2013) · Drug Science Policy and Law · doi:10.1177/2050324513509190 · Cited by 6
“It is an extremely useful drug, used as an antidepressant and also may be an effective agent for smoking cessation (Stahl et al., 2004).”
BackgroundMohammadi-Mahdiabadi-Hasani, M.-H., Ebrahimi-Ghiri, M., Khakpai, F., & Zarrindast, M. (2022) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-022-02242-2 · Cited by 6
“Therefore, bupropion is considered an antidepressant with unique pharmacologic properties with specific tolerability (Stahl et al. 2004).”
BackgroundCardiac pathologic findings in 3 unusual cases of sudden cardiac death related to anorexiant drugs
Leone, O., Agostini, V., Foà, A., Cerbelli, B., Gioia, C. R. T. D., Aromatario, M., Ciallella, C., Lucena, J., & d’Amati, G. (2017) · Human Pathology · doi:10.1016/j.humpath.2017.09.014 · Cited by 6
Paternal exposure to bupropion affects postnatal development in the offspring
Sanches, E. S., Tsuzuki, F., Joinhas, F. A., Figueiras, G. B., Moreira, E. G., & Salles, M. J. S. (2019) · Reproduction Fertility and Development · doi:10.1071/rd18403 · Cited by 6
McKendrick, G., Sharma, S., Sun, D., Randall, P. A., & Graziane, N. (2020) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2020.173638 · Cited by 6
Barman, R., Kumar, S., Pagadala, B., & Detweiler, M. B. (2017) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000729 · Cited by 6
Treatment of tobacco dependence: current state of the art
Kathuria, H., Leone, F. T., & Neptune, E. (2018) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0000000000000491 · Cited by 6
Alsoqih, N. S., Elmorsy, E. A., Abu‐Khudir, R., Saber, S., Keshk, N., Elnaghy, F., Hamad, R. S., El-kott, A. F., Negm, S., AlShehri, M. A., et al. (2025) · The FASEB Journal · doi:10.1096/fj.202501829rr · Cited by 5
“Effects of bupropion therapy occur through blocking norepinephrine and dopamine reuptake and thus increasing the neurotransmitter concentrations in the synaptic cleft [105].”
State-dependent memory mechanisms insights from neural circuits and clinical implications
Liu, Y., Zhang, G., Qi, R., Ma, J., & Xu, J. (2025) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2025.1629796 · Cited by 5
Aikoye, S., Basiru, T., Nwoye, I., Adereti, I., Asuquo, S. E., Ezeokoli, A., Hardy, J., & Umudi, O. (2023) · Cureus · doi:10.7759/cureus.36189 · Cited by 8
“The most common (four cases) desired effect of abusing bupropion was a cocaine-like high (some high similar to cocaine) [13,14,24,28] while amphetamine-like high, (some high similar to amphetamine), “get high,” depression treatment, possible recreational use, and “brief buzz” were other common reasons why patients abu…”
BackgroundInfluentialHu, Y., Velu, P., Rohani, P., & Sohouli, M. H. (2023) · European Journal of Clinical Investigation · doi:10.1111/eci.14122 · Cited by 6
Comerma-Steffensen, S., Kun, A., Prat‐Duran, J., Mogensen, S., Alan, E., Fais, R. S., Munro, G., Peters, D., & Simonsen, U. (2024) · British Journal of Pharmacology · doi:10.1111/bph.16362 · Cited by 5
“The antidepressant drug bupropion not only inhibits the dopamine uptake transporter ( DAT ) but also inhibits the noradrenaline uptake transporter ( NAT ) and is a nicotinic receptor antagonist (Stahl et al., 2004).”
BackgroundSeki, Y., Mikamoto, M., Ojima, A., Mihara, I., Iwamoto, M., Odawara, A., Goto, Y., Taniguchi, T., Shiotani, M., Yoshinaga, T., et al. (2025) · Toxicological Sciences · doi:10.1093/toxsci/kfaf056 · Cited by 5
Effects of bupropion on the ejaculatory response of male rats
Hueletl-Soto, M. E., Carro-Juárez, M., & Rodríguez–Manzo, G. (2014) · International Journal of Impotence Research · doi:10.1038/ijir.2014.12 · Cited by 5
(2014) · Receptors & Clinical Investigation · doi:10.14800/rci.65 · Cited by 7
Drug-induced sleepiness and insomnia: an update
Gonçalves, R. T., & Togeiro, S. M. (2013) · Sleep Science · doi:10.1055/s-0046-1820387 · Cited by 5
“same time, both pathways related to wakefulness; it can cause insomnia in approximately 10% of its users(41).”
Amundson, C. J., Knight, R., Ybarra, G., Turgeon, J., & Bingham, J. M. (2022) · Medicina · doi:10.3390/medicina58030438 · Cited by 5
“Bupropion, a mainstay of antidepressant augmentation, increases dopamine and norepinephrine via inhibition of reuptake, however, aripiprazole occupies the dopamine 2 receptor for weeks at a time, blocking the effect [24,25].”
BackgroundGupta, J. K., Singh, K., Bhatt, A., Porwal, P., Rani, R., Dubey, A., Jain, D., & Nand, S. (2024) · 3 Biotech · doi:10.1007/s13205-024-04104-5 · Cited by 5
“…a substance that inhibits the Dopamine transporter (DAT), and either an SNRI or SSRI, which are substances that inhibit the absorption of serotonin and norepinephrine, respectively, is more effective in treating depression compared to using only one of these substances (Stahl et al. 2004).”
Co-occurring anxiety and depression: concepts, significance, and treatment implications
McGrath, P. J., & Miller, J. M. (2010) · Cambridge University Press eBooks · doi:10.1017/cbo9780511777578.011 · Cited by 5
Augmentation of Venlafaxine With Bupropion
Andrade, C. (2013) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.13f08348 · Cited by 5
“Because the J Clin Psychiatry 2013;74(2):e119–e121 (doi:10.”
Takayanagi, T., Itoh, D., & Mizuguchi, H. (2016) · Chromatography · doi:10.15583/jpchrom.2016.009 · Cited by 5
"Abuses and Misuses of Benzodiazepines and Antidepressents; A Review"
Arshad, S. (2018) · Modern applications in Pharmacy & Pharmacology · doi:10.31031/mapp.2018.01.000521 · Cited by 5
“Benzodiazepine are generally taken orally snorted and by intravenous injection among high risk opioids user [15].”
BackgroundThe effect of bupropion augmentation of minocycline in the treatment of depression
Bendale, M., D'souza, S. R., Addepalli, V., & Kale, P. P. (2019) · Acta Neurobiologiae Experimentalis · doi:10.21307/ane-2019-019 · Cited by 5
“Due to its dual action, it is considered a drug of interest in the treatment of depression (Stahl et al., 2004).”
BackgroundThe synthesis of novel type of α-aminoketones containing allomaltol fragment
Komogortsev, A. N., Melekhina, V. G., & Lichitsky, B. V. (2020) · Synthetic Communications · doi:10.1080/00397911.2020.1849725 · Cited by 5
Rose, J. E., Willette, P. N., Botts, T. L., Botts, D. R., & Behm, F. M. (2022) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2022.109346 · Cited by 5
Bupropion and Panic Disorder: Case Report and Review of the Literature
Serafini, G., Pompili, M., Fusar‐Poli, P., Porfiri, G., Giordano, G., Ferracuti, S., Girardi, P., & Tatarelli, R. (2011) · Journal of Neuropsychiatry · doi:10.1176/appi.neuropsych.23.2.e47 · Cited by 5
Brunskill, D. (2010) · The British Journal of Psychiatry · doi:10.1192/bjp.196.5.353 · Cited by 5
Le, G. H., & McIntyre, R. S. (2026) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2026.2619757 · Cited by 4
“In approved formulations, DXM is co-administered with bupro-pion primarily to inhibit cytochrome P450 family 2 subfamily D member 6 (CYP2D6)-mediated metabolism and thereby enhance DXM bioavailability, rather than to directly modulate NMDA receptor signaling [13– 111 ].”
Song, Y., Park, Y., Lee, D. H., Yee, J., & Gwak, H. S. (2024) · Psychiatry Research · doi:10.1016/j.psychres.2024.115874 · Cited by 4
McCurdy, M. T., Narayanan, R., Dalton, J., Herczeg, C. K., Heard, J. C., Lee, Y. A., Giakas, A. M., Boyajieff, E., Glover, A., Sumughan, S., et al. (2024) · World Neurosurgery · doi:10.1016/j.wneu.2024.10.142 · Cited by 4
Andrés, C. M. C., de la Lastra, J. M. P., Munguira, E. B., Andrés, C., & Pérez‐Lebeña, E. (2024) · Molecules · doi:10.3390/molecules29245918 · Cited by 4
“Naphyrone (naphthylpyrovalerone was marketed in the UK under the name “Energy-1” (NRG-1) as a legal alternative to mephedrone [41,57]. naphthalene known as naphyrone (naphthylpyrovalerone, O-2482), which is a mixture of alpha”
Żełabowski, K., Petrov, W., Ślebioda, D., Rusinek, M., Biedka, K., Błaszczyk, K., Wesołowski, M., Wojtysiak, K., Sroka, M., Ratka, Z., et al. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14186470 · Cited by 4
“Consequently, it is evident that the medication does not elicit adverse effects that are associated with other antidepressants, including weight gain, lethargy, or sexual dysfunction [152].”
Warlick, H., Tocci, D. R., Prashar, S., Boldt, E. A., Khalil, A., Arora, S., Matthews, T., Wahid, T., Fernandez, R., Ram, D., et al. (2024) · Psychopharmacology · doi:10.1007/s00213-024-06686-7 · Cited by 4
“Consequently, the side effect profiles of dry mouth, nausea, and insomnia of the medication differ from the stereotypical side effects of anti-depressants (Stahl et al. 2004 ; Dhillon et al. 2008 ).”
Neurotransmitter modulation of human facial emotion recognition
Vlazaki, M., Harmer, C. J., Cowen, P. J., & Pulcu, E. (2025) · Journal of Psychopharmacology · doi:10.1177/02698811251338225 · Cited by 4
“The effects of bupropion, a dual inhibitor of noradrenaline and dopamine uptake and clinically used as an antidepressant (Stahl et al., 2004), have also been studied with regards to FER.”
In vitro/in vivoevaluation of agarnanospheres forpulmonarydelivery of bupropion HCl
Varshosaz, J., Minaiyan, M., Zaki, M. R., Fathi, M., & Jaleh, H. (2015) · Drug Delivery · doi:10.3109/10717544.2015.1025314 · Cited by 4
“Bupropion HCl is an antidepressant of the aminoketone class which inhibits the reuptake of dopamine and norepinephrine (Laizure et al., 1985; Stahl et al., 2004; Brunton et al., 2006).”
BackgroundSchwitalla, T., Patel, R. A., Catalano, G., & Nirmalani-Gandhy, A. (2019) · Clinical Neuropharmacology · doi:10.1097/wnf.0000000000000364 · Cited by 4
“The therapeutic effect of bupropion is presumed to be, in part, owing to the antidepressant activity of 3 active metabolites: hydroxybupropion, threohydrobupropion, and erythrohydrobupropion.(1) These active metabolites have been shown in vivo to inhibit the actions of both DA and NE without affecting serotonin (5-HT).”
BackgroundInfluentialOlivier, J. D. A., Janssen, J. A., Pattij, T., Prêtre, S. D., & Olivier, B. (2022) · Neuromethods · doi:10.1007/978-1-0716-2083-0_20 · Cited by 5
Bupropion-Induced Dystonia: A Case Report
Zahra, T., Voloshyna, D., Bseiso, A., Shaik, T. A., Ferman, H., Sathish, M., Barznji, S. A., Saleem, F., & Ghaffari, M. A. Z. (2022) · Cureus · doi:10.7759/cureus.29857 · Cited by 4
“Bupropion is used to treat major depressive disorder (MDD), is a medical aid for smoking cessation, and is also used as the alternative treatment of choice for MDD patients with sexual dysfunction caused by serotonin reuptake inhibitors (SSRIs) [1,2].”
BackgroundInfluentialCulprits of Medication-Induced Telogen Effluvium, Part 1
Zhang, D., LaSenna, C., & Shields, B. E. (2023) · Cutis · doi:10.12788/cutis.0910 · Cited by 4
Bupropion-Induced Erythema Multiforme
Evrensel, A., & Ceylan, M. E. (2015) · Annals of Dermatology · doi:10.5021/ad.2015.27.3.334 · Cited by 4
Bupropion Augmentation in a Case of Compulsive Buying Disorder
Sepede, G., Iorio, G. D., Sarchione, F., Fiori, F., & Giannantonio, M. D. (2017) · Clinical Neuropharmacology · doi:10.1097/wnf.0000000000000232 · Cited by 4
“The inhibition of dopamine reuptake could explain its anticraving and antiwithdrawal effects and its promising role in the treatment of dual-diagnosed patients.(38) In conclusion, using combined therapies with different psychopharmacological agents, such asmirtazapine and bupropion, could be a useful strategy in the m…”
BackgroundLapointe, T., Francis, T., Doray, K., & Leri, F. (2023) · Neuropharmacology · doi:10.1016/j.neuropharm.2023.109572 · Cited by 3
Sun, H., Chen, J., Wu, X.-X., & Wang, Z. (2025) · PLoS ONE · doi:10.1371/journal.pone.0336021 · Cited by 3
“Bupropion is a norepinephrine–dopamine re-uptake inhibitor with mild anticholinergic and negative allosteric effects on certain nAChR subtypes, and it can slow intestinal transit and reducing secretions [10].”
InfluentialTargeting Dopaminergic System for Treating Nicotine Dependence
Abuhamdah, S. M. A., Khalil, A. A., & Sari, Y. (2016) · Central Nervous System Agents in Medicinal Chemistry · doi:10.2174/1871524916666151104115421 · Cited by 4
Bupropion-Associated Galactorrhea: A Case Report
Çam, B., & Bilgin, A. A. (2014) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000242 · Cited by 3
Zhu, J. Q., Coppens, R. P., Rabinovich, N. E., & Gilbert, D. G. (2017) · Experimental and Clinical Psychopharmacology · doi:10.1037/pha0000109 · Cited by 3
Review on analytical methods for quantification of ADHD drugs in human biological samples
Sundari, J., Amuthalakshmi, S., & Nalini, C. N. (2020) · Reviews in Analytical Chemistry · doi:10.1515/revac-2020-0114 · Cited by 3
Consensus statements on the clinical understanding and use of bupropion in Hong Kong
Lee, W., Yeung, K. L. A., Lam, H., Wong, C., Wong, T., Fu, C., Sham, S. K., Au, M. K., Lam, T., & Mak, K. (2021) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.13376 · Cited by 3
Avey, J. P., Schaefer, K. R., Noonan, C., Trinidad, S. B., Muller, C. J., Claw, K. G., Dillard, D. A., Todd, M. R., Beans, J. A., Tyndale, R. F., et al. (2023) · Nicotine & Tobacco Research · doi:10.1093/ntr/ntad133 · Cited by 3
Jiang, Q., Velu, P., Sohouli, M. H., Ziamanesh, F., Shojaie, S., Fatahi, S., & Li, Q. (2023) · European Journal of Clinical Investigation · doi:10.1111/eci.14118 · Cited by 3
Bupropion is effective in depression in narcolepsy
Yavuz, B. G., Mercan, S., & Karamustafalıoğlu, O. (2005) · International Journal of Psychiatry in Clinical Practice · doi:10.1080/13651500500241454 · Cited by 3
“Bupropion with its metabolites inhibit reuptake at human transporters for both dopamine and norepinephrine, with slightly greater fuctional potency at the dopamine transporter than the norepinephrine transporter [13].”
BackgroundPerceptual Disturbances Associated With Low-Dose Bupropion Sustained-Release Treatment
Liu, C.-Y., & Chien, Y.-S. (2007) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31814fb98e · Cited by 3
Recurrent Isolated Sleep Paralysis Following Bupropion Cessation: A Case Report
Bieber, E. D., Bieber, D. A., Romanowicz, M., Voort, J. L. V., Kolla, B. P., & McKean, A. J. S. (2019) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000001051 · Cited by 4
Trigo, J. M., & Foll, B. L. (2019) · Methods in molecular biology · doi:10.1007/978-1-4939-9554-7_11 · Cited by 3
The Overlap Between Sleep Disorders and Psychiatric Disorders
Rao, N. P. (2020) · Springer eBooks · doi:10.1007/978-3-030-44447-1_17 · Cited by 4
Omri, M., Ferhi, M., Rauschenbach, C., Ibrahim, A. A., Galvao, M. O., & Hamm, O. (2024) · Cureus · doi:10.7759/cureus.73980 · Cited by 2
Tranchida, N., Inferrera, F., Cuzzocrea, S., Cordaro, M., & Paola, R. D. (2025) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2025.111458 · Cited by 2
“The selective inhibition of dopamine reuptake and norepinephrine is the precise therapy mechanism for major depressive disorder, however it is not entirely understood (Stahl et al., 2004).”
Bupropion-induced acute dystonia in a patient with bulimia nervosa: A case report
Rashidpour, P., Poursharif, Z., Ayatollahi, M., & Farzannejad, E. (2021) · Journal of Family Medicine and Primary Care · doi:10.4103/jfmpc.jfmpc_1173_20 · Cited by 2
“[2,3] On the other hand, it may result inadverse effects such as nausea, dry mouth, headache, insomnia, dizziness, anxiety, tremor, and constipation.[3,4] Some case studies have reported that patients are likely to experience dose‐related acute dystonic adverse responses to bupropion in the presence or absence of busp…”
BackgroundShamsi, F., Sheibani, A., & Shishehbore, M. R. (2023) · Analytical Sciences · doi:10.1007/s44211-023-00371-z · Cited by 2
Polypharmacologic Toxicity Involving Deutetrabenazine in a Patient With Renal Insufficiency
Pudukodu, H. S., Radhakrishnan, V., & Rosen, J. H. (2023) · Journal of the Academy of Consultation-Liaison Psychiatry · doi:10.1016/j.jaclp.2023.08.004 · Cited by 2
Pramipexole for the Treatment of Depression: Efficacy and Mechanisms
Halahakoon, D. C., & Browning, M. D. (2023) · Current topics in behavioral neurosciences · doi:10.1007/7854_2023_458 · Cited by 2
Nebenwirkungen der neuen Antidepressiva
Lenz, F., Bauer, M. W., & Ritter, P. S. (2018) · Fortschritte der Neurologie · Psychiatrie · doi:10.1055/a-0648-1760 · Cited by 2
Vadiei, N., Smith, T. L., & Garcia-Pittman, E. C. (2018) · Mental Health Clinician · doi:10.9740/mhc.2018.07.188 · Cited by 2
“Bupropion is an antidepressant with a distinct side effect profile.(2) Initial studies(3,4) comparing bupropion sustained release to placebo-treated patients reported that the most common adverse events were dry mouth, nausea, and insomnia, respectively.”
BackgroundAbrudan, M. B., Popa, D., Muntean, D. M., Gheldiu, A. M., & Vlase, L. (2019) · Medicine and Pharmacy Reports · doi:10.15386/mpr-1225 · Cited by 3
“Bupropion is a dual norepinephrine and dopamine reuptake inhibitor used as antidepressant medication to treat major depressive disorder or seasonal affective disorder [9].”
BackgroundTreatment of Maternal Depression in a Medication Clinical Trial and Its Effect on Children
Weissman, M. M., WICKRAMARATNE, P. J., Pilowsky, D. J., Poh, E., Batten, L. A., Hernández, M., Flament, M. F., Stewart, J. A., McGrath, P. J., Blier, P., et al. (2016) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/appi.focus.140103 · Cited by 3
Psychopharmaka-induzierte unerwünschte Wirkungen in der Ernährungstherapie
Schlumm, K., Sina, C., Schröder, T., & Smollich, M. (2019) · Aktuelle Ernährungsmedizin · doi:10.1055/a-0942-9167 · Cited by 2
“Es wird aber vermutet, dass die Dopamin- und Noradrenalin-Reuptake-Hemmung, wie sie bei Bupropion der Fall ist, eine entscheidende Rolle spielt, da diese Eigenschaft mit der Regulierung von Appetit und Sättigung assoziiert ist [29].”
BackgroundMaternal Gestational Weight Gain in Relation to Antidepressant Continuation in Pregnancy
Wartko, P. D., Weiss, N. S., Enquobahrie, D. A., Chan, K. C. G., Stephenson‐Famy, A., Mueller, B. A., & Dublin, S. (2020) · American Journal of Perinatology · doi:10.1055/s-0040-1713652 · Cited by 2
Advances in Depression Management
Ingram, M., Maguire, G. A., & Stahl, S. M. (2021) · Advances in Psychiatry and Behavioral Health · doi:10.1016/j.ypsc.2021.05.001 · Cited by 2
Self-citationBupropion-induced leukopenia: A case report (eng)
Gürcan, G., & Gürcan, A. (2021) · Journal of Clinical Psychiatry · doi:10.5505/kpd.2021.02419 · Cited by 2
“Common side effects of bupropion are dry mouth, nausea and insomnia (4), also it may lower the seizure threshold (2).”
InfluentialMoran, A. E., Huynh, Y. W., Finkner, A., Selleck, C., Thompson, A., Barrett, S. T., & Bevins, R. A. (2022) · Psychopharmacology · doi:10.1007/s00213-022-06072-1 · Cited by 2
“Bupropion (Zyban®), originally marketed in the USA in 1989 as an atypical antidepressant (Stahl et al. 2004), is a non-nicotinic cessation aid that helps control cravings and ameliorates withdrawal from nicotine dependence (Hurt et al.”
BackgroundUse of Bupropion in the Management of Negative Symptom Schizophrenia: A Case Series
Perera, P., Gajaram, G., Qureshi, D., Gill, M., Thanju, A., Zaman, A., Fouron, P., & Jolayemi, A. (2022) · Cureus · doi:10.7759/cureus.23518 · Cited by 2
“Preclinical and clinical data have shown that bupropion’s mechanism of action is via the dual inhibition of norepinephrine and dopamine reuptake (NDRI), constituting a novel and unique mechanism of antidepressant action with efficacy comparable to that of other antidepressants [22].”
BackgroundResultWu, P. E., & Juurlink, D. N. (2016) · Springer eBooks · doi:10.1007/978-3-319-20790-2_135-1 · Cited by 2
Ahmed, H., Ismayl, M., Palicherla, A., Selim, M., & Aboeata, A. (2024) · Annals of Medicine and Surgery · doi:10.1097/ms9.0000000000002175 · Cited by 2
“While the speci fi cs of bupropion ’ s pharmacological mechanisms remain not fully understood, It is thought that bupropion inhibits the reuptake of both dopamine and norepinephrine, with a limited effect on serotonin reuptake [5,6] .”
BackgroundLADER, M. H. (2011) · Clinical Drug Investigation · doi:10.2165/11596410-000000000-00000 · Cited by 2
Garelli, S., Salituro, N., Pontesilli, G. M., Ricciardiello, L., Vicennati, V., & Pagotto, U. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.65344-8 · Cited by 2
The Mental Health and Well Being of Older Adults in Hospice and Palliative Care
Arnold, M. E. (2022) · Advances in Family Practice Nursing · doi:10.1016/j.yfpn.2022.01.001 · Cited by 1
Clinical Pipelines for Alzheimer’s Disease Psychosis and Agitation
Oguma, T., & Jino, K. (2024) · Chemical and Pharmaceutical Bulletin · doi:10.1248/cpb.c23-00416 · Cited by 2
Analytical Methods for Tetracyclic Antidepressants: A Comprehensive Review
Shetty, S. R., Rathore, S. S. S., & Jenita⃰, J. J. L. (2024) · Separation Science Plus · doi:10.1002/sscp.202400157 · Cited by 1
Simon, M. W., Brent, J. A., Brandehoff, N., & Camarena-Michel, A. (2025) · Journal of Emergency Medicine · doi:10.1016/j.jemermed.2025.03.013 · Cited by 1
Smith, S. N., & Holahan, M. R. (2025) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2025.111442 · Cited by 1
Suzuki, M., Koyama, D., Hidema, S., Misaka, S., Wada, I., Maejima, Y., & Shimomura, K. (2025) · Neuroreport · doi:10.1097/wnr.0000000000002197 · Cited by 2
PHARMACOLOGICAL TREATMENT STRATEGIES FOR ADHD: A SYSTEMATIC REVIEW
Grzesikowski, P., Klich, P., Bekier, K., Kubiak, J., Górski, J., Nowicka, H., Liszka, D., Joks, M. M., Ordon, E., & Ostromecka, K. (2025) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.3(47).2025.3814 · Cited by 1
Shariatzadeh, N., & Wakhlu, S. (2026) · Cureus · doi:10.7759/cureus.102744 · Cited by 1
“BUP, an atypical antidepressant with norepinephrine-dopamine reuptake inhibition (NDRI) and antagonism of certain nicotinic acetylcholine receptors, has shown some efficacy in treating both cocaine and methamphetamine use disorder [13].”
Bupropion Toxicity Presenting As Alcohol Withdrawal Syndrome: A Case Report
Nguyen, D., Faradji, D., Frangenberg, A., & Haq, S. (2026) · Cureus · doi:10.7759/cureus.106899 · Cited by 1
“It is also commonly used off-label for anxiety disorders, attention-deficit/hyperactivity disorder, bipolar disorder, and obesity [2].”
Task-aligned outcome learning in psychiatry: reducing endpoint dilution
Strobl, E. V. (2026) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2026.1832978 · Cited by 4
Metadata
- Authors
- Stahl, S. M., Pradko, J., Haight, B. R., Modell, J. G., Rockett, C. B., & Learned-Coughlin, S.
- Affiliations
- University of California San Diego (US)
- St. John Hospital & Medical Center (US)
- Corresponding author
- Modell, Jack G.
- ORCID
- Stahl, Stephen M.
- Venue
- The Primary Care Companion For CNS Disorders
- Publisher
- Physicians Postgraduate Press, Inc
- Published
- 2004-08-13
- Volume
- 6
- Issue
- 4
- Pages
- 159-166
- ISSN
- 2155-7772 (ISSN-L)
- 2155-7780
- PMC
- PMC514842
- OpenAlex
- W2046809238
- Cited by
- 495
- References
- 92
- Citations by year
- 2026: 14 · 2025: 28 · 2024: 31 · 2023: 33 · 2022: 35 · 2021: 27 · 2020: 27 · 2019: 19 · 2018: 36 · 2017: 25 · 2016: 29 · 2015: 23 · 2014: 19 · 2013: 20 · 2012: 15
- FWCI
- 8.57
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- The Primary Care Companion For CNS Disorders (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Keywords
- bupropion, norepinephrine reuptake inhibition, dopamine uptake inhibition, antidepressant mechanism, antidepressant efficacy, antidepressant tolerability, sexual dysfunction, weight gain, sedation, serotonergic effects
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.